Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis

New England Journal of Medicine

Volumn 344, Issue 9, 2001, Pages 626-631

  Breddin, Hans Klaus ^a   Hach Wunderle, Viola ^a   Nakov, Roumen ^a   Kakkar, Vijay V ^a  

^a International Institute of Thrombosis and Vascular Diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEG THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; RETROPERITONEAL HEMORRHAGE;

ACUTE DISEASE; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; PULMONARY EMBOLISM; RECURRENCE; SINGLE-BLIND METHOD; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

EID: 0035283104     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103013440902     Document Type: Article

References (34)

1. Management of heparin therapy: Controlled prospective trial
2. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
3. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
4. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism - An overview
5. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): Results of a double-blind randomized study
6. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: A collaborative European multicentre study
7. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg
8. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
9. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
10. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
11. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
12. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
13. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
14. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
15. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin
16. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
17. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
18. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
19. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis
20. A multicenter clinical trial comparing once and twice-daily deep vein thrombosis
21. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
22. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
23. Treatment of deep venous thrombosis with low-molecular-weight heparins: A meta-analysis
24. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism (Cochrane review)
25. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy
26. Efficacy of low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis
27. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk
28. Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trials
29. "Proving the null hypothesis" in clinical trials
30. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
31. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
32. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin
33. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis
34. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis